Results 231 to 240 of about 126,024 (329)

Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

Acta Pharmacologica Sinica, 2020
Zhong-jie Li, Hui-qi Dai, Xiao-wei Huang, Ji Feng, Jing-Huan Deng, Zi-Xuan Wang, Xiao-Mei Yang, Yu-jia Liu, Yuehua Wu, Pan-hong Chen, Huan Shi, Ji-Gang Wang, Jing Zhou, Guo-Dong Lu   +13 more
semanticscholar   +1 more source

Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. [PDF]

Mol Cancer
Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.   +11 more
europepmc   +1 more source

Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms. [PDF]

Cell Death Dis
Qi D, Qin Y, Zhu H, Li Y, Han S.
europepmc   +1 more source

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial. [PDF]

Cancers (Basel)
Handa S, Koenig K, Zhao Q, Mims AS, Vasu S, Garzon R, Haque T, Benson D, Klisovic RB, Marcucci G, Walker AR, Bhatnagar B.   +11 more
europepmc   +1 more source

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma [PDF]

, 2014
Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel, Syma Iqbal, I-Y Gong, Kenneth C. Micetich, Omar Kayaleh, H-J Lenz, Charles D. Blanke   +8 more
openalex   +1 more source

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. [PDF]

Front Immunol
Li Z, He J, Ma K.
europepmc   +1 more source

The Safety and Efficacy of Sorafenib Combined with Transarterial Chemoembolization For Patients with Unresectable Hepatocellular Carcinoma

, 2012
Wenyu Shao, Ning Cong, Jinlong Song
openalex   +1 more source

Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma [PDF]

, 2016
Hsin‐An Chen, Tsang‐Chih Kuo, Chi‐Feng Tseng, Jui‐Ti Ma, Shuting Yang, Chia‐Jui Yen, Ching‐Yao Yang, Shian‐Ying Sung, Jen‐Liang Su   +8 more
openalex   +1 more source

Sorafenib-Loaded Polyelectrolyte Complex Nanoparticles: <i>In vitro</i> and <i>in vivo</i> Studies

, 2022
Sangita A. Kale, Karimunnisa Sameer Shaikh   +1 more
openalex   +1 more source

PFKL Inhibition by DT-13: A Novel Approach to Combat Hepatocellular Carcinoma. [PDF]

Int J Hepatol
Yu Q, Hu L, Tan C, Gao M, Wen Z.
europepmc   +1 more source